References
- Smolen JS, Aletaha D. Forget personalised medicine and focus on abating disease activity. Ann Rheum Dis. 2013;72(1):3–6.
- Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
- Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheumatism. 2009;60(5):1232–1241.
- Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011;38(5):846–854.
- Hammaker DR, Boyle DL, Chabaud-Riou M, et al. Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Iimmunol. 2004;172(3):1612–1618.
- Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124(3):244–257.
- Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303–1312.
- Weinblatt ME, Kavanaugh A, Genovese MC, et al. Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol. 2013;40(4):369–378.
- Changelian PS, Flanagan ME, Ball DJ. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science. 2003;302(5646):875–878.
- Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;2(8657):244–247.
- Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheumatism. 2002;46(12):3143–3150.
- Valenzuela F, Korman NJ, Bissonnette R. et al. Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study. Br J Dermatol. 2018;179(4):853–862.
- Meshkov AD, Novikov PI, Zhilyaev EV, et al. Tofacitinib in steroid-dependent relapsing polychondritis. Ann Rheum Dis. 2018.
- Tavakolpour S. Tofacitinib as the potent treatment for refractory pemphigus: A possible alternative treatment for pemphigus. Dermatol Ther. 2018;31(5):e12696.
- Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: A case series. Dermatol Ther. 2018;31(6):e12656.
- Liu LY, Bg C, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–28.
- Damsky W, Thakral D, Emeagwali N, et al. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379(26):2540–2546.
- Paley MA, Karacal H, Rao PK, et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–55.
- Gok K, Cengiz G, Erol K. et al. Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial mediterranean fever. Acta Reumatol Port. 2017;42(1):88–90.
- Kochar B, Herfarth N, Mamie C. et al. Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol. 2019;17(5):991–993.
- Busque S, Vincenti FG, Tedesco Silva H. et al. Efficacy and safety of a Tofacitinib-based immunosuppressive regimen after kidney transplantation: results from a long-term extension trial. Transplant Direct. 2018;4(9):e380.
- Lomonte ABV, Radominski SC, Marcolino FMD. et al. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: pooled efficacy and safety analyses. Medicine (Baltimore). 2018;97(31):e11609.
- Li Z, An Y, Su H. et al. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: patient-reported outcomes from a Phase 3 randomized controlled trial. Int J Rheum Dis. 2018;21(2):402–414.
- Hall S, Nash P, Rischmueller M. et al. Tofacitinib, an oral janus kinase inhibitor: pooled efficacy and safety analyses in an Australian rheumatoid arthritis population. Rheumatol Ther. 2018.
- Vencovsky J, Badurski J, Forejtová Š. et al. Tofacitinib safety and efficacy in the treatment of rheumatoid arthritis in a Central/Eastern European subpopulation [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/tofacitinib-safety-and-efficacy-in-the-treatment-of-rheumatoid-arthritis-in-a-central-eastern-european-subpopulation/.
- Dhillon S. Tofacitinib: A review in rheumatoid arthritis. Drugs. 2017;77(18):1987–2001.
- Takeuchi T, Smolen JS, Fleischmann R. et al. Clinical and functional response to tofacitinib and adalimumab in patients with rheumatoid arthritis: probability plot analysis of results from the ORAL strategy trial [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/clinical-and-functional-response-to-tofacitinib-and-adalimumab-in-patients-with-rheumatoid-arthritis-probability-plot-analysis-of-results-from-the-oral-strategy-trial/.
- Strand V, Kavanaugh A, Kivitz AJ. et al. Long-term radiographic and patient-reported outcomes in patients with rheumatoid arthritis treated with Tofacitinib: ORAL start and ORAL scan post-hoc analyses. Rheumatol Ther. 2018.
- Fleischmann R, Wollenhaupt J, Cohen S, et al. Effect of discontinuation or initiation of methotrexate or glucocorticoids on tofacitinib efficacy in patients with rheumatoid arthritis: a post Hoc analysis. Rheumatol Ther. 2018;5(1):203–214.
- Van Vollenhoven RF, Lee EB, Fallon L. et al. Tofacitinib in rheumatoid arthritis: lack of early change in disease activity predicts a low probability of achieving low disease activity at month 6. Arthritis Care Res (Hoboken). 2019;71(1):71–79.
- Fleischmann R, Mease PJ, Schwartzman S. et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clin Rheumatol. 2017;36(1):15–24.
- Takeuchi T, Yamanaka H, Yamaoka K. et al. Efficacy and safety of tofacitinib in Japanese patients with rheumatoid arthritis by background methotrexate dose: a post-hoc analysis of clinical trial data. Mod rheumatol Jpn Rheumatism Assoc. 2018; 1–20.
- Charles-Schoeman C, van der Heijde D, Burmester GR. et al. Effect of glucocorticoids on the clinical and radiographic efficacy of tofacitinib in patients with rheumatoid arthritis: a posthoc analysis of data from 6 phase III studies. J Rheumatol. 2018;45(2):177–187.
- Fleischmann R, Kremer J, Cush J. et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507.
- Kremer JM, Rigby W, Singer NG, et al. Sustained response following discontinuation of methotrexate in patients with rheumatoid arthritis treated with subcutaneous tocilizumab: results from a randomized, controlled trial. Arthritis Rheumatol. 2018;70(8):1200–1208.
- Fautrel BZB, Taylor PC, van de Laar M, et al. Comparative effectiveness in pain and HAQ-DI improvement for baricitinib versus adalimumab, tocilizumab, and tofacitinib monotherapies in csdmard-naïve rheumatoid arthritis patients: a matching-adjusted indirect comparison (MAIC) [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/comparative-effectiveness-in-pain-and-haq-di-improvement-for-baricitinib-versus-adalimumab-tocilizumab-and-tofacitinib-monotherapies-in-csdmard-naive-rheumatoid-arthritis-patients-a/.
- Bae SC, Lee YH. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Z Rheumatol. 2018 Sep 6. DOI:10.1007/s00393-018-0531-5. [Epub ahead of print]
- Caporali R, Zavaglia D. Real-world experience with tofacitinib for treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2018 Aug 29. [Epub ahead of print]
- Cohen S, Curtis JR, DeMasi R. et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5(1):283–291.
- Mori S, Yoshitama T, Ueki Y. Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-naive and experienced patients. Int Med. 2018;57(5):663–670.
- Iwamoto N, Tsuji S, Takatani A, et al. Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PloS one. 2017;12(5):e0177057.
- Cohen S, Haraoui B, Curtis J. et al. Comparative analysis of outcomes among patients with rheumatoid arthritis initiating tofacitinib in combination with oral MTX who discontinue, interrupt, or persist with MTX [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/comparative-analysis-of-outcomes-among-patients-with-rheumatoid-arthritis-initiating-tofacitinib-in-combination-with-oral-mtx-who-discontinue-interrupt-or-persist-with-mtx/.
- Machado MAA, Moura CS, Guerra SF, et al. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018;20(1):60.
- Hsieh S, Chen Y, Chen W. et al. Real-world use of tofacitinib compared with tumor necrosis factor inhibitors in a cohort of 211 patients with rheumatoid arthritis: data from a drug-based registry study in Taiwan [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/real-world-use-of-tofacitinib-compared-with-tumor-necrosis-factor-inhibitors-in-a-cohort-of-211-patients-with-rheumatoid-arthritis-data-from-a-drug-based-registry-study-in-taiwan/.
- Finckh A, Tellenbach C, Scherer A. et al. The impact of comedication with conventional synthetic dmards on drug retention and clinical effectiveness of tofacitinib, anti–tumor necrosis factor therapy and biologics with an alternative mode of action in patients with rheumatoid arthritis. a cohort study [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/the-impact-of-comedication-with-conventional-synthetic-dmards-on-drug-retention-and-clinical-effectiveness-of-tofacitinib-anti-tumor-necrosis-factor-therapy-and-biologics-with-an-alternative/.
- Mueller R, Hasler C, Popp F. et al. Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world DATA from the ST. Gallen and-Aarau RA-Cohort [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/effectiveness-tolerability-and-safety-of-tofacitinib-in-rheumatoid-arthritis-a-retrospective-analysis-of-real-world-data-from-the-st-gallen-and-aarau-ra-cohort/.
- Meißner Y, Baganz L, Schneider M. et al. Baricitinib and tofacitinib in real life – does obesity impact response to janus kinase inhibitor therapy in rheumatoid arthritis? [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/baricitinib-and-tofacitinib-in-real-life-does-obesity-impact-response-to-janus-kinase-inhibitor-therapy-in-rheumatoid-arthritis/.
- Kubo S, Yamaoka K, Amano K, et al. Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology. 2017;56(8):1293–1301.
- Perez-Roman DI, Ortiz-Haro AB, Ruiz-Medrano E, et al. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Rheumatol Int. 2018;38(4):599–606.
- Dikranian A, Wollenhaupt J, Azevedo V. et al. Frequency and duration of early non-serious adverse events in rheumatoid arthritis patients treated with tofacitinib 5 Mg twice daily as monotherapy and combination therapy [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/frequency-and-duration-of-early-non-serious-adverse-events-in-rheumatoid-arthritis-patients-treated-with-tofacitinib-5-mg-twice-daily-as-monotherapy-and-combination-therapy/.
- Kivitz AJ, Cohen S, Keystone E. et al. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a phase 3 rheumatoid arthritis population. Semin Arthritis Rheum. 2018;48(3):406–415.
- Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017;76(7):1253–1262.
- Cohen S, Tanaka Y, Mariette X. et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the RA clinical development program [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/long-term-safety-of-tofacitinib-up-to-9-5-years-a-comprehensive-integrated-analysis-of-the-ra-clinical-development-program/.
- Maeshima K, Yamaoka K, Kubo S, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheumatism. 2012;64(6):1790–1798.
- Sonomoto K, Yamaoka K, Kubo S, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology. 2014;53(5):914–918.
- van Vollenhoven R, Lee EB, Strengholt S. et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2018.
- Soriano ER, Madariaga H, Castañeda O. et al. Liver Enzyme Abnormalities after Tofacitinib Treatment in Patients with Hepatic Steatosis from the Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Clinical Programs [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/liver-enzyme-abnormalities-after-tofacitinib-treatment-in-patients-with-hepatic-steatosis-from-the-rheumatoid-arthritis-psoriatic-arthritis-and-psoriasis-clinical-programs/.
- Kremer J, Cappelli LC, Etzel CJ. et al. Real-world data from a post-approval safety surveillance study of tofacitinib vs biologic dmards and conventional synthetic dmards: five-year results from a US-based rheumatoid arthritis registry [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/real-world-data-from-a-post-approval-safety-surveillance-study-of-tofacitinib-vs-biologic-dmards-and-conventional-synthetic-dmards-five-year-results-from-a-us-based-rheumatoid-arthritis-registry/.
- Tamura N, Kuwana M, Atsumi T. et al. Malignancy in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim analysis of all-case post-marketing surveillance [abstract]. Arthritis Rheumatol. 2018;70(suppl10). Avaliable from: https://acrabstracts.org/abstract/malignancy-in-japanese-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-interim-analysis-of-all-case-post-marketing-surveillance/.
- Yamaoka K. Benefit and risk of tofacitinib in the treatment of rheumatoid arthritis: a focus on herpes zoster. Drug Saf. 2016.
- Winthrop KL, Curtis JR, Lindsey S. et al. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol. 2017;69(10):1960–1968.
- Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15–23.
- Koike T, Harigai M, Inokuma S. et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod rheumatol Jpn Rheumatism Assoc. 2011;21(4):343–351.
- Koike T, Harigai M, Ishiguro N. et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients. Mod rheumatol Jpn Rheumatism Assoc. 2014;24(3):390–398.
- Onuora S. Immunology: metabolic changes modify treg cell function. Nat Rev Rheumatol. 2016;12(11):621.
- Onuora S. Fibromyalgia: optic nerve damaged in patients with fibromyalgia. Nat Rev Rheumatol. 2016;12(11):622.
- Kugelberg E. Autoimmunity: infection stimulates self-antigen presentation. Nat Rev Immunol. 2016;16(9):534–535.
- Tamura N, Kuwana M, Atsumi T. et al. Infection events in japanese patients with rheumatoid arthritis treated with tofacitinib: Interim all-case post-marketing surveillance [abstract]. Arthritis Rheumatol. 2018;70(suppl10). Avaliable from: https://acrabstracts.org/abstract/infection-events-in-japanese-patients-with-rheumatoid-arthritis-treated-with-tofacitinib-interim-all-case-post-marketing-surveillance/.
- Curtis JR, Xie F, Yang S. et al. Herpes zoster in tofacitinib: Risk is further increased with glucocorticoids but not methotrexate. Arthritis Care Res (Hoboken). 2018 Oct 8. DOI:10.1002/acr.23769. [Epub ahead of print].
- Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847.
- Winthrop KL, Wouters AG, Choy EH. et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: A randomized phase II trial. Arthritis Rheumatol. 2017;69(10):1969–1977.
- Lal H, Cunningham AL, Godeaux O. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
- Vink P. Immunogenicity and safety of a candidate subunit adjuvanted herpes zoster vaccine (hz/su) in adults post renal transplant: a phase III randomized clinical trial. Open Forum Infect Dis. 2017;4(Suppl 1):S417.
- Vink P, Ramon Torrell JM, Sanchez-Fructuoso AI, et al. Twelve-month immunogenicity and safety of an adjuvanted recombinant zoster vaccine in immunosuppressed adults post renal transplant: a phase III randomized clinical trial. Open Forum Infect Dis. 2018;5(Suppl 1):S744.
- Baricitinib (LY3009104) Rheumatoid Arthritis FDA Advisory Committee Meeting. 2018. Advisory Committee Briefing Materials: Available for Public Release. Avaliable from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/arthritisadvisorycommittee/ucm605062.pdf.
- Mease PJ, Kremer J, Cohen S. et al. Incidence of thromboembolic events in the tofacitinib rheumatoid arthritis, psoriasis, psoriatic arthritis and ulcerative colitis development programs [abstract]. Arthritis Rheumatol. 2017;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/incidence-of-thromboembolic-events-in-the-tofacitinib-rheumatoid-arthritis-psoriasis-psoriatic-arthritis-and-ulcerative-colitis-development-programs/.
- Genovese M, Smolen J, Takeuchi T. et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 6 years: an updated integrated safety analysis. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/safety-pro.
- Yun H, Xie F, Chen L. et al. Risk of venous thrombotic events in rheumatoid arthritis patients initiating tofacitinib or adalimumab [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/risk-of-venous-thrombotic-events-in-rheumatoid-arthritispatients-initiating-tofacitinib-or-adalimumab/.
- Desai RJ, Pawar A, Weinblatt ME. et al. Comparative risk of venous thromboembolism with tofacitinib versus tumor necrosis factor inhibitors: A cohort study of rheumatoid arthritis patients [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: Rhttps://acrabstracts.org/abstract/comparative-risk-of-venous-thromboembolism-with-tofacitinibversus-tumor-necrosis-factor-inhibitors-a-cohort-study-of-rheumatoid-arthritis-patients/.
- Verden A, Dimbil M, Kyle R. et al. Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf. 2018;41(4):357–361.
- Raaschou P, Soderling J, Turesson C, et al. Tumor necrosis factor inhibitors and cancer recurrence in Swedish Patients with rheumatoid arthritis: A nationwide population-based cohort study. Ann Intern Med. 2018;169(5):291–299.
- Mariette X, Chen C, Biswas P. et al. Lymphoma in the tofacitinib rheumatoid arthritis clinical development program. Arthritis Care Res (Hoboken). 2018;70(5):685–694.
- Curtis JR, Lee EB, Martin G. et al. Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme. Clin Exp Rheumatol. 2017;35(4):614–622.
- van der Heijde D, Strand V, Tanaka Y. et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic and safety outcomes from the 24-month phase 3 ORAL scan study. Arthritis Rheumatol. 2019 Jan 22. DOI:10.1002/art.40803. [Epub ahead of print].
- Citera G, Mysler E, Madariaga H. et al. Low interstitial lung disease event rate in patients with rheumatoid arthritis: Pooled post hoc analysis of data from the tofacitinib clinical development program [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/low-interstitial-lung-disease-event-rate-in-patients-with-rheumatoid-arthritis-pooled-post-hoc-analysis-of-data-from-the-tofacitinib-clinical-development-program/.
- Ozen G, Pedro S, Michaud K. Cardiovascular disease risk with biologics and tofacitinib compared to conventional synthetic dmards in patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2018;70(suppl 10). Avaliable from: https://acrabstracts.org/abstract/cardiovascular-disease-risk-with-biologics-and-tofacitinib-compared-to-conventional-synthetic-dmards-in-patients-with-rheumatoid-arthritis/.
- Singh S, Fumery M, Singh AG. et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2019.
- Nurmohamed M, Choy E, Lula S. et al. The impact of biologics and tofacitinib on cardiovascular risk factors and outcomes in patients with rheumatic disease: a systematic literature review. Drug Saf. 2018;41(5):473–488.
- Nishida K, Harada R, Nasu Y. et al. The clinical course of patients with rheumatoid arthritis who underwent orthopaedic surgeries under disease control by tofacitinib. Mod rheumatol Jpn Rheumatism Assoc. 2018;28(6):1063–1065.
- Barroso NS, Miller EZ, Furst DE. A case series on patients on tofacitinib in combination with a biologic. J Clin Rheumatol Pract Rep Rheumatic Musculoskeletal Dis. 2018;24(6):349–351.
- Watanabe T, Hattori T, Ogawa Y. et al. Successful treatment with tofacitinib for renal disorder due to amyloid A amyloidosis and immunoglobulin A nephropathy in a patient with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36(4):683–684.
- Yamamoto M, Yokoyama Y, Shimizu Y. et al. Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis. Mod rheumatol Jpn Rheumatism Assoc. 2016;26(4):633–634.
- Smolen JS, Landewe R, Bijlsma J. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977.
- Burmester GR, Kivitz AJ, Kupper H. et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis. 2015;74(6):1037–1044.
- Strangfeld A, Hierse F, Kekow J. et al. Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis. 2009;68(12):1856–1862.
- Shimaoka H, Takeno S, Maki K. et al. A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer. Oncol Lett. 2017;14(3):3019–3027.
- Breedveld FC, Weisman MH, Kavanaugh AF. et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheumatism. 2006;54(1):26–37.
- Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann Rheum Dis. 2009;68(7):1171–1176.
- Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. BMC Musculoskelet Disord. 2011;12:54.